IL1B and myocardial infarction: Administration of anti-IL-1β monoclonal antibody reduced the relative risk of major adverse cardiovascular events by up to 25%, in addition to the 31% decline in cardiovascular and overall mortality in patients with a history of myocardial infarction [46].